Summary
GlobalData's Medical Devices sector report, “Immunosuppressant Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019" provides an overview of Immunosuppressant Therapeutic Drug Monitoring currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Immunosuppressant Therapeutic Drug Monitoring pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Immunosuppressant Therapeutic Drug Monitoring under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Immunosuppressant Therapeutic Drug Monitoring and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Immunosuppressant Therapeutic Drug Monitoring under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
'
Table of Contents
1.1 List of Tables 4
1.2 List of Figures 6
2 Introduction 7
2.1 Immunosuppressant Therapeutic Drug Monitoring Overview 7
3 Products under Development 8
3.1 Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 8
3.2 Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Territory 9
3.3 Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Regulatory Path 10
3.4 Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Estimated Approval Date 11
4 Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products under Development by Companies 12
4.1 Immunosuppressant Therapeutic Drug Monitoring Companies - Pipeline Products by Stage of Development 12
4.2 Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 13
5 Immunosuppressant Therapeutic Drug Monitoring Companies and Product Overview 15
5.1 Abbott Diagnostics Company Overview 15
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 15
5.2 BIOHOPE Scientific SL Company Overview 16
5.2.1 BIOHOPE Scientific SL Pipeline Products & Ongoing Clinical Trials Overview 16
5.3 Laboratory Corp of America Holdings Company Overview 17
5.3.1 Laboratory Corp of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 17
5.4 Ortho-Clinical Diagnostics Inc Company Overview 18
5.4.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 18
5.5 Progenika Biopharma SA Company Overview 22
5.5.1 Progenika Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview 22
5.6 Roche Diagnostics International Ltd Company Overview 23
5.6.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 23
5.7 Siemens Healthcare Diagnostics Inc Company Overview 43
5.7.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 43
6 Immunosuppressant Therapeutic Drug Monitoring- Recent Developments 49
6.1 Nov 05, 2019: Thermo Fisher Scientific highlights expanded pharma services capabilities during CPhI 49
6.2 Oct 29, 2019: Waters reports third quarter 2019 financial results 50
6.3 Oct 23, 2019: Thermo Fisher Scientific reports third quarter 2019 results 51
6.4 Sep 24, 2019: Theradiag announces improved results for H1 2019 53
6.5 Sep 19, 2019: SenzaGen presents a new commercial organization and a new financial target 56
6.6 Sep 11, 2019: Mark Beaudouin to retire as Waters General Counsel; Company promotes Keeley Aleman 57
6.7 Sep 05, 2019: Thermo Fisher Scientific elects New Director to Board 57
6.8 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 58
6.9 Aug 28, 2019: Waters names Jonathan M. Pratt as President of TA Instruments 58
6.10 Aug 06, 2019: Aurinia reports second quarter 2019 financial results and operational highlights 59
7 Appendix 92
7.1 Methodology 92
7.2 About GlobalData 95
7.3 Contact Us 95
7.4 Disclaimer 95
List of Tables
Table 1: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 9
Table 2: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Territory 10
Table 3: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Regulatory Path 11
Table 4: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Estimated Approval Date 12
Table 5: Immunosuppressant Therapeutic Drug Monitoring Companies - Pipeline Products by Stage of Development 13
Table 6: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 14
Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 17
Table 8: Alinity i Assay - Methotrexate - Product Status 17
Table 9: Alinity i Assay - Methotrexate - Product Description 17
Table 10: BIOHOPE Scientific SL Pipeline Products & Ongoing Clinical Trials Overview 18
Table 11: Immunobiogram - Renal Transplantation - Product Status 18
Table 12: Immunobiogram - Renal Transplantation - Product Description 18
Table 13: Laboratory Corp of America Holdings Pipeline Products & Ongoing Clinical Trials Overview 19
Table 14: DoseASSURE RTX Assay - Product Status 19
Table 15: DoseASSURE RTX Assay - Product Description 19
Table 16: Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 21
Table 17: VITROS XT 7600 Integrated System - Cedia Cyclosporine Assay - Product Status 21
Table 18: VITROS XT 7600 Integrated System - Cedia Cyclosporine Assay - Product Description 21
Table 19: VITROS XT 7600 Integrated System - Cedia Mycophenolic Acid Assay - Product Status 22
Table 20: VITROS XT 7600 Integrated System - Cedia Mycophenolic Acid Assay - Product Description 22
Table 21: VITROS XT 7600 Integrated System - Methotrexate Assay - Product Status 22
Table 22: VITROS XT 7600 Integrated System - Methotrexate Assay - Product Description 24
Table 23: VITROS XT 7600 Integrated System - QMS Everolimus Assay - Product Status 24
Table 24: VITROS XT 7600 Integrated System - QMS Everolimus Assay - Product Description 24
Table 25: VITROS XT 7600 Integrated System - QMS Tacrolimus Assay - Product Status 25
Table 26: VITROS XT 7600 Integrated System - QMS Tacrolimus Assay - Product Description 25
Table 27: Progenika Biopharma SA Pipeline Products & Ongoing Clinical Trials Overview 26
Table 28: Promonitor - Autoimmune And Inflammation - Product Status 26
Table 29: Promonitor - Autoimmune And Inflammation - Product Description 26
Table 30: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 28
Table 31: Cobas - Cyclosporin A Assay - Product Status 30
Table 32: Cobas - Cyclosporin A Assay - Product Description 30
Table 33: Cobas - Everolimus Assay - Product Status 31
Table 34: Cobas - Everolimus Assay - Product Description 31
Table 35: Cobas 4000 Analyzer Series With e 411 Module - Cyclosporine Assay - Product Status 31
Table 36: Cobas 4000 Analyzer Series With e 411 Module - Cyclosporine Assay - Product Description 32
Table 37: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Status 32
Table 38: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Description 32
Table 39: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Status 33
Table 40: Cobas 4000 Analyzer Series With e 411 Module - Sirolimus Assay - Product Description 33
Table 41: Cobas 6000 Analyzer Series With c 501 Module - Cyclosporine Assay - Product Status 33
Table 42: Cobas 6000 Analyzer Series With c 501 Module - Cyclosporine Assay - Product Description 33
Table 43: Cobas 6000 Analyzer Series With c 501 Module - Everolimus Assay - Product Status 34
Table 44: Cobas 6000 Analyzer Series With c 501 Module - Everolimus Assay - Product Description 34
Table 45: Cobas 6000 Analyzer Series With c 501 Module - Sirolimus Assay - Product Status 34
Table 46: Cobas 6000 Analyzer Series With c 501 Module - Sirolimus Assay - Product Description 35
Table 47: Cobas 6000 Analyzer Series With c 501 Module - Tacrolimus Assay - Product Status 35
Table 48: Cobas 6000 Analyzer Series With c 501 Module - Tacrolimus Assay - Product Description 35
Table 49: Cobas 6000 Analyzer Series With e 601 Module - Cyclosporine Assay - Product Status 35
Table 50: Cobas 6000 Analyzer Series With e 601 Module - Cyclosporine Assay - Product Description 36
Table 51: Cobas 6000 Analyzer Series With e 601 Module - Everolimus Assay - Product Status 36
Table 52: Cobas 6000 Analyzer Series With e 601 Module - Everolimus Assay - Product Description 36
Table 53: Cobas 6000 Analyzer Series With e 601 Module - Sirolimus Assay - Product Status 37
Table 54: Cobas 6000 Analyzer Series With e 601 Module - Sirolimus Assay - Product Description 38
Table 55: Cobas 6000 Analyzer Series With e 601 Module - Tacrolimus Assay - Product Status 38
Table 56: Cobas 6000 Analyzer Series With e 601 Module - Tacrolimus Assay - Product Description 38
Table 57: Cobas 8000 Analyzer Series With c 502 Module - Cyclosporine Assay - Product Status 38
Table 58: Cobas 8000 Analyzer Series With c 502 Module - Cyclosporine Assay - Product Description 39
Table 59: Cobas 8000 Analyzer Series With c 502 Module - Everolimus Assay - Product Status 39
Table 60: Cobas 8000 Analyzer Series With c 502 Module - Everolimus Assay - Product Description 39
Table 61: Cobas 8000 Analyzer Series With c 502 Module - Sirolimus Assay - Product Status 40
List of Figures
Figure 1: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Stage of Development 8
Figure 2: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Territory 9
Figure 3: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Regulatory Path 10
Figure 4: Immunosuppressant Therapeutic Drug Monitoring - Pipeline Products by Estimated Approval Date 11
